NCT04293380View on ClinicalTrials.gov

Amniotic Fluid Ischemia Modified Albumin as a Novel e Prenatal Diagnostic Marker for Down Syndrome

NACompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 1, 2012

Primary Completion Date

June 1, 2016

Study Completion Date

September 1, 2016

Conditions
Down SyndromePrenatal StressCytokines
Interventions
PROCEDURE

amniosyntesis

Trial Locations (1)

61100

Karadeniz Technical Universty Medical School, Trabzon

All Listed Sponsors
lead

Karadeniz Technical University

OTHER

NCT04293380 - Amniotic Fluid Ischemia Modified Albumin as a Novel e Prenatal Diagnostic Marker for Down Syndrome | Biotech Hunter | Biotech Hunter